Alkermes Q4 2022 Earnings Report
Key Takeaways
Alkermes plc reported Q4 2022 financial results, with total revenues of $304.7 million compared to $324.5 million for the same period in the prior year. GAAP net loss was $28.3 million, or a loss of $0.17 per share, while non-GAAP net income was $24.2 million, or $0.14 per share.
Total revenues for the quarter were $304.7 million, compared to $324.5 million for the same period in the prior year.
Net sales of proprietary products for the quarter were $216.1 million, compared to $178.9 million for the same period in the prior year.
GAAP net loss for the quarter was $28.3 million, or a basic and diluted GAAP loss per share of $0.17.
Non-GAAP net income for the quarter was $24.2 million, or a non-GAAP diluted earnings per share of $0.14.
Alkermes
Alkermes
Alkermes Revenue by Segment
Forward Guidance
The company provided financial expectations for 2023, reflecting the combined neuroscience and oncology business for the full year, anticipating continued growth of proprietary products and investment in a direct-to-consumer campaign to support the launch of LYBALVI.
Positive Outlook
- Total Revenue $1,130 – $1,250 million
- VIVITROL Net Sales $380 – $410 million
- ARISTADA Net Sales $315 – $345 million
- LYBALVI Net Sales $180 – $205 million
- INVEGA Franchise Royalties $25 – $30 million
Challenges Ahead
- GAAP Net Loss ($160) – ($200) million
- GAAP Net Loss per Share ($0.96) – ($1.20)
- Non-GAAP Net Income $0 – $40 million
- Non-GAAP Net Earnings Per Share (Diluted) $0.00 – $0.23
- Capital Expenditures $35 – $40 million
Revenue & Expenses
Visualization of income flow from segment revenue to net income